Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $19.2M | $19.5M | $33.3M |
| Revenue growth | — | 1.8% | 71.0% |
| Gross profit | $16.8M | $15.4M | $20.9M |
| Gross margin | 88.0% | 79.2% | 62.8% |
| Net income | $3.96M | $670K | $1.28M |
| Net margin | 20.7% | 3.4% | 3.8% |
| EPS (diluted) | — | $0.01 | $0.02 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | $1.53M | $2.18M | $3.13M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $2.42M | $7.85M | $7.67M |
| Total assets | $11.5M | $15.8M | $23.1M |
| Total liabilities | $5.41M | $2.60M | $5.98M |
| Shareholders' equity | $6.09M | $13.2M | $17.1M |
| Retained earnings | $3.27M | $3.94M | $5.22M |
| Shares (wtd avg diluted) | — | 53.7M | 57.7M |
Every figure is extracted from Health In Tech, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.